What Abbott Structural Heart does

Abbott Structural Heart is a business division of Abbott Laboratories (NYSE: ABT) that develops and commercializes minimally invasive and surgical medical devices for the treatment of structural heart disease, stroke risk reduction, and congenital heart defects. Headquartered at 3200 Lakeside Dr, Santa Clara, California, the division operates through direct enterprise field sales to hospitals and certified heart clinics, where interventional cardiologists, cardiac surgeons, echocardiographers, and valve coordinators deploy its devices within multidisciplinary heart teams. The unit's revenue model is hardware sales of one-time-use medical devices sold through institutional hospital procurement; device pricing is not publicly disclosed and is negotiated facility-by-facility.

The portfolio is organized in three pillars. Transcatheter Valve Solutions include the MitraClip and TriClip G5 Transcatheter Edge-to-Edge Repair (TEER) systems (with Controlled Gripper Actuation for simultaneous or independent leaflet grasping), the Tendyne transcatheter mitral valve replacement system (the first FDA-approved TMVR for severe mitral annular calcification), and the Navitor transcatheter aortic valve implantation (TAVI) system. Surgical Valve Solutions comprise Epic porcine tissue valves and the Masters Series/Regent mechanical heart valves. Structural Interventions cover the Amplatzer occluder family: Amulet LAAO, Talisman PFO, Septal Occluder, DUCT Occluder, Piccolo Occluder (approved for premature infants from 700 g), and VSD Occluders including a post-infarct muscular variant. The portfolio is supported by physician mobile apps (Amplatzer Portfolio App, Heart Valves App), clinical evidence publications, an ongoing slate of more than 45 clinical trials, and reimbursement/coding infrastructure.

Customer segments include patients with valvular heart disease (mitral, tricuspid, and aortic), patients with non-valvular atrial fibrillation or PFO-associated stroke, and patients from neonates through adults with congenital defects such as ASD, VSD, and PDA. The division maintains both U.S. and international commercial presences with reimbursement tracking, valve-coordinator training, and patient-facing programs such as Little Heroes; clinical evidence endpoints (e.g., 47% relative risk reduction in HFH/death at 5 years for MitraClip vs. GDMT; 99% effective LAA closure at 3 years for Amulet) anchor physician adoption and category leadership claims across the portfolio.

Name

Abbott Structural Heart

Legal name

Abbott

Website

https://structuralheart.abbott

Company type

Public

Operating status

Operating

Short description

Abbott Structural Heart, a division of Abbott Laboratories, develops and commercializes minimally invasive transcatheter and surgical medical devices for the treatment of valvular heart disease, stroke risk, and congenital heart defects, selling to hospitals and certified heart teams worldwide.

Ownership category

akta.pro rank

Product category

Structural Heart Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB)

Keywords

• Structural heart devices
• Transcatheter valve repair
• Transcatheter aortic valve
• Cardiac occluder devices
• Heart valve replacement

Headquarters

HQ city

Santa Clara

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Medical Device Sales: Abbott Structural Heart generates revenue through the sale of proprietary medical devices including transcatheter valve repair/replacement systems, surgical valves, and structural heart occluder devices. Revenue is generated through one-time device sales to hospitals and healthcare facilities where procedures are performed.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Abbott Structural Heart develops and sells a portfolio of transcatheter and surgical medical devices for the treatment of structural heart diseases. Its offering includes transcatheter edge-to-edge repair (TEER) systems (MitraClip, TriClip), transcatheter mitral valve replacement (Tendyne), transcatheter aortic valve implantation (Navitor), surgical tissue and mechanical heart valves, and the Amplatzer occluder family for stroke risk reduction and congenital heart defect closure. Products are sold to hospitals and heart centers where certified physicians perform the procedures.

Product overview

Abbott Structural Heart Solutions offers a comprehensive portfolio of medical devices across three main categories: Transcatheter Valve Solutions (including MitraClip and TriClip TEER systems, Tendyne TMVR, and Navitor TAVI System), Surgical Valve Solutions (Epic Tissue Heart Valves, Masters Series and Regent Mechanical Heart Valves), and Structural Interventions (Amplatzer occluder family including Amulet LAAO, Talisman PFO, Septal Occluder, DUCT Occluders, Piccolo Occluder, and VSD Occluders). The portfolio addresses conditions including valvular heart disease, stroke risk factors, and congenital heart defects through minimally invasive transcatheter procedures and surgical interventions.

Differentiator

Problem solved

Functional benefit

Products and services

• MitraClip Transcatheter Edge-to-Edge Repair (TEER) system for treating mitral regurgitation. Established leader in transcatheter mitral valve repair with over 20 years of experience and more than 250,000 patients treated worldwide. Intended for use by interventional cardiologists and cardiac surgeons in hospitals and heart centers.
• TriClip Transcatheter Edge-to-Edge Repair (TEER) system designed specifically for the tricuspid valve. Minimally invasive treatment for patients with symptomatic severe tricuspid regurgitation who are at intermediate or greater risk for surgery. For use by multidisciplinary heart teams in hospitals.
• Tendyne First FDA-approved transcatheter mitral valve replacement (TMVR) system for treating symptomatic severe mitral valve dysfunction associated with severe mitral annular calcification (MAC) in patients unsuitable for mitral valve surgery or TEER. Features interprocedurally recapturable, repositionable, and retrievable design with tether-based securement. For high-risk structural heart patients.
• Navitor TAVI System

Quantifiable outcome

• MitraClip therapy demonstrated 47% relative risk reduction in HFH/death versus GDMT-alone at 5 years
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Edwards Lifesciences: Edwards Lifesciences is the global leader in TAVI/TAVR with the SAPIEN platform and is Abbott's most direct competitor in transcatheter structural heart. Edwards also competes in TEER via the PASCAL system, directly challenging MitraClip and TriClip in mitral and tricuspid repair.
• Boston Scientific: Boston Scientific is a direct competitor in structural interventions, particularly the Watchman FLX left atrial appendage closure device that competes with the Amplatzer Amulet LAAO, and is expanding into transcatheter valve technologies.
• Medtronic: Medtronic competes head-to-head with Abbott Structural Heart across TAVI (Evolut platform), structural heart occluders, and emerging TMVR (Intrepid). Its broad cardiovascular portfolio and global hospital sales footprint make it a direct structural heart competitor.
• Artivion (formerly CryoLife): Artivion is a specialist in tissue heart valves and cardiac repair products, directly comparable to Abbott's Epic tissue heart valve and surgical valve repair portfolio. Both companies serve cardiac surgeons in surgical valve replacement.
• LivaNova: LivaNova manufactures mechanical heart valves and other cardiac surgery products, directly comparable to Abbott's Masters Series and Regent mechanical heart valve portfolio. It is a focused structural heart and cardiac surgery competitor.

Emerging players

• Conformal Medical: Conformal Medical is developing next-generation left atrial appendage closure technology, directly competing with Abbott's market-leading Amplatzer Amulet LAAO franchise in the structural stroke-risk-reduction segment.
• Venus Medtech: Venus Medtech is a Chinese structural heart company developing transcatheter valve replacement systems, including TAVI and TMVR programs. It is a relevant emerging competitor in the same transcatheter structural heart category as Abbott.
• Cardiac Dimensions: Cardiac Dimensions develops the Carillon system for tricuspid and functional mitral regurgitation, a transcatheter therapy that competes indirectly with Abbott's MitraClip and TriClip repair franchises in the tricuspid space.
• 4C Medical Technologies: 4C Medical is an early-stage TMVR company developing the AltaValve system for mitral regurgitation, directly competing with Abbott's Tendyne TMVR platform and representing a long-term threat to the broader TEER/TMVR market.
• JenaValve Technology: JenaValve is an emerging transcatheter aortic valve player focused on aortic regurgitation, a structural heart segment adjacent to Abbott's Navitor TAVI. It represents a new generation of TAVI competitors targeting indications Abbott does not currently address.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/AbbottCardio
• YouTubeyoutube.com/c/AbbottCardiovascular/playlists?view=50&shelf_id=7
• Facebookfacebook.com/Abbott
• LinkedInlinkedin.com/company/1612

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abbott Structural Heart